Annual Report

Overview

The report highlights the company's 2024 strategic development agreement with GE HealthCare and the FDA clearance of its Investigational New Drug application for the Phase 2 ENACT trial. It also describes the company's small operating footprint, with 12 employees at year-end, and reports no data breaches during 2024. The report presents these developments alongside ongoing work to advance ultrasound-mediated drug delivery in oncology.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services